TECH

Bio-Techne Corporation
CAPPED RATING

Bio-Techne Corp and is a biotechnology company which develops, manufactures and sells biotechnology reagents, instruments and clinical diagnostic products.

Bio-Techne Corporation (TECH) is rated C+ (2.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B+); its weakest is Revisions (D+).

Quantitative Factor Evaluation • Updated

Overall Rating
2.5 / 5.0
C+
Value
C-
Factor Score 2.0 / 5.0
Growth
C-
Factor Score 2.0 / 5.0
Profitability
B
Factor Score 3.2 / 5.0
Momentum
B+
Factor Score 3.8 / 5.0
Revisions
D+
Factor Score 1.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 66.8
EV / EBITDA 34.9
Rev Growth YoY 4.6%
Gross Margin 66.2%
Price Return 3M 0.8%
Price Return 12M 19.4%
Catalyst Signal +0.02
Market Cap $11.4B
TTM Revenue $1.2B
Price / Sales 9.3
ROE 8.3%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-16 C- (2.0) C- (2.0) B (3.2) B+ (3.8) D+ (1.6) C+ (2.5)
2026-11-09 C- (2.0) C- (2.0) B (3.2) B+ (3.7) F (0.3) C (2.2)
2026-11-02 C- (2.1) C- (2.1) B (3.2) B (3.4) F (0.3) C (2.2)
2026-10-27 C- (2.1) C- (2.1) B (3.2) B (3.2) F (0.5) C (2.2)
2026-10-26 C- (2.1) C- (2.1) B (3.2) B (3.2) C- (2.0) C+ (2.5)
Page 1 of 9
…